Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis.
HIPEC
cytoreductive surgery
morbidity
mortality
peritoneal surface malignancies
risk factors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Nov 2022
25 Nov 2022
Historique:
received:
04
11
2022
revised:
22
11
2022
accepted:
24
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy may significantly improve survival for selected patients with peritoneal surface malignancies, but it has always been criticized due to the high incidence of postoperative morbidity and mortality. Data were collected from nine Italian centers with peritoneal surface malignancies expertise within a collaborative group of the Italian Society of Surgical Oncology. Complications and mortality rates were recorded, and multivariate Cox analysis was used to identify risk factors. The study included 2576 patients. The procedure was mostly performed for ovarian (27.4%) and colon cancer (22.4%). The median peritoneal cancer index was 13. Overall postoperative morbidity and mortality rates were 34% and 1.6%. A total of 232 (9%) patients required surgical reoperation. Multivariate regression logistic analysis identified the type of perfusion ( Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a valuable option of treatment for selected patients with peritoneal carcinomatosis providing low postoperative morbidity and mortality rates, if performed in high-volume specialized centers.
Sections du résumé
BACKGROUND
BACKGROUND
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy may significantly improve survival for selected patients with peritoneal surface malignancies, but it has always been criticized due to the high incidence of postoperative morbidity and mortality.
METHODS
METHODS
Data were collected from nine Italian centers with peritoneal surface malignancies expertise within a collaborative group of the Italian Society of Surgical Oncology. Complications and mortality rates were recorded, and multivariate Cox analysis was used to identify risk factors.
RESULTS
RESULTS
The study included 2576 patients. The procedure was mostly performed for ovarian (27.4%) and colon cancer (22.4%). The median peritoneal cancer index was 13. Overall postoperative morbidity and mortality rates were 34% and 1.6%. A total of 232 (9%) patients required surgical reoperation. Multivariate regression logistic analysis identified the type of perfusion (
CONCLUSIONS
CONCLUSIONS
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a valuable option of treatment for selected patients with peritoneal carcinomatosis providing low postoperative morbidity and mortality rates, if performed in high-volume specialized centers.
Identifiants
pubmed: 36497306
pii: cancers14235824
doi: 10.3390/cancers14235824
pmc: PMC9741330
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Hyperthermia. 2018 Aug;34(5):532-537
pubmed: 28838265
J Gastrointest Surg. 2020 Jan;24(1):165-176
pubmed: 31745888
J Surg Res. 2019 Feb;234:103-109
pubmed: 30527460
JAMA Netw Open. 2019 Jan 4;2(1):e186847
pubmed: 30646202
Ann Surg Oncol. 2018 Jan;25(1):91-97
pubmed: 29090402
Ann Surg Oncol. 2018 Mar;25(3):709-719
pubmed: 29282602
Langenbecks Arch Surg. 2015 Jan;400(1):37-48
pubmed: 25319432
Langenbecks Arch Surg. 2021 Dec;406(8):2817-2825
pubmed: 34686891
Eur J Surg Oncol. 2021 Sep;47(9):2358-2362
pubmed: 33895028
Ann Surg. 2009 Jun;249(6):900-7
pubmed: 19474692
J Gastrointest Oncol. 2019 Apr;10(2):235-243
pubmed: 31032090
Am J Surg. 2020 Mar;219(3):478-483
pubmed: 31558307
World J Surg Oncol. 2020 Apr 6;18(1):67
pubmed: 32252768
J Surg Oncol. 2021 Mar;123(4):1030-1044
pubmed: 33524164
Ann Surg. 2012 Aug;256(2):334-41
pubmed: 22580946
Langenbecks Arch Surg. 2019 Aug;404(5):541-546
pubmed: 31352505
Surg Oncol Clin N Am. 2018 Jul;27(3):495-506
pubmed: 29935685
Cancers (Basel). 2019 Jan 11;11(1):
pubmed: 30641919
JAMA Surg. 2014 Feb;149(2):170-5
pubmed: 24352601
Surg Oncol Clin N Am. 2003 Jul;12(3):703-27, xiii
pubmed: 14567026
World J Gastrointest Oncol. 2020 Jul 15;12(7):756-767
pubmed: 32864043
Ann Surg Oncol. 2018 Dec;25(13):3950-3959
pubmed: 30302637
Ann Surg Oncol. 2016 Jun;23(6):1941-7
pubmed: 26842489
Cancer Med. 2019 Jun;8(6):2877-2885
pubmed: 31033239
Surg Endosc. 2018 May;32(5):2288-2294
pubmed: 29218669
J Gastrointest Surg. 2014 May;18(5):1024-31
pubmed: 24577736
Surgeon. 2018 Oct;16(5):278-282
pubmed: 29429947
Ann Surg Oncol. 2021 Jul;28(7):3823-3830
pubmed: 33165722
Ann Surg Oncol. 2021 Sep;28(9):5287-5296
pubmed: 33486643
J Am Coll Surg. 2014 Apr;218(4):573-85
pubmed: 24491244
Eur J Surg Oncol. 2019 Dec;45(12):2412-2423
pubmed: 31444027
J Surg Oncol. 2016 Jun;113(7):796-803
pubmed: 27110915
Ann Surg Oncol. 2021 Aug;28(8):4499-4507
pubmed: 33507449
J Surg Res. 2019 Dec;244:395-401
pubmed: 31325661
Ann Surg. 2021 Nov 1;274(5):797-804
pubmed: 34334647
J Surg Oncol. 2019 Sep;120(4):794-802
pubmed: 31309588
Cancers (Basel). 2020 Aug 23;12(9):
pubmed: 32842535
Ann Surg Oncol. 2021 Oct;28(11):6613-6624
pubmed: 34304310
Ann Surg Oncol. 2018 Oct;25(11):3264-3270
pubmed: 30051371
Ann Surg Oncol. 2019 Oct;26(11):3652-3662
pubmed: 31359273
Ann Surg. 2020 Nov;272(5):847-854
pubmed: 32833761
Gynecol Oncol. 2021 Aug;162(2):368-374
pubmed: 34083027
Eur J Surg Oncol. 2021 Jan;47(1):143-148
pubmed: 32888734
Ann Surg Oncol. 2021 Dec;28(13):9060-9070
pubmed: 34057569
Ann Surg Oncol. 2020 Apr;27(4):1084-1093
pubmed: 31641950
Surg Oncol Clin N Am. 2018 Jul;27(3):507-517
pubmed: 29935686
Ann Surg Oncol. 2019 Feb;26(2):490-496
pubmed: 30515670
Ann Surg Oncol. 2020 Jan;27(1):222-231
pubmed: 31222683
Ann Surg Oncol. 2014 May;21(5):1494-500
pubmed: 23990289
Langenbecks Arch Surg. 2019 Aug;404(5):527-539
pubmed: 31377856
J Gastrointest Surg. 2020 Sep;24(9):2096-2103
pubmed: 31432327
Ann Surg Oncol. 2017 Dec;24(13):3825-3830
pubmed: 29019118
Surg Oncol. 2021 Jun;37:101492
pubmed: 33465587
Clin Transl Oncol. 2019 Apr;21(4):451-458
pubmed: 30218305
J Surg Res. 2020 Nov;255:475-485
pubmed: 32622162
J Surg Res. 2019 Feb;234:240-248
pubmed: 30527480
Int J Clin Oncol. 2020 May;25(5):984-994
pubmed: 31915944
J Surg Res. 2019 Jan;233:360-367
pubmed: 30502272
Ann Surg Oncol. 2019 Jan;26(1):148-154
pubmed: 30456672